CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,083 enrolled
Drug / intervention
abiraterone +10 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05701007
NCT05701007N/ACompleted
CompareCT.gov

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Pfizer·observational·Posted Jan 26, 2023·Updated Jan 29, 2026

In Brief

An observational study evaluating abiraterone, enzalutamide, and 9 other interventions for Metastatic Castration Sensitive Prostate Cancer (mCSPC) and Metastatic Castration Resistant Prostate Cancer (mCRPC). Completed, enrolled 1,083 participants across 1 site.

Detailed Summary

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
CountriesFinland
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJan 26, 2023
Enrollment StartFeb 13, 2023
Primary CompletionApr 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.4 years ago

Interventions

abirateronedrug

mCRPC

enzalutamidedrug

mCRPC

docetaxeldrug

mCRPC

apalutamidedrug

mCRPC

cabazitaxeldrug

mCRPC

Radium-223drug

mCRPC

Lutetium-177drug

mCRPC

degarelixdrug

mCSPC

goserelindrug

mCSPC

leuprorelindrug

mCSPC

triptorelindrug

mCSPC